Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

9

US Approved OTC

2

Other

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Cyclooxygenase-1

5

Cyclooxygenase-2

5

Bacterial penicillin-binding protein

4

Solute carrier family 22 member 11

4

Solute carrier family 22 member 6

4

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

11

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1976

5

1984

4

1974

2

Unknown

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Ankylosing spondylitis

5

Bursitis

5

Osteoarthritis

5

Rheumatoid arthritis

5

Tendonitis

5

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

7

Curative

6

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

6

CNS Active

5

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Syntex

5

Hoffman-La Roche

4

Janssen

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

12

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

12

FDA UNII

12

PUBCHEM

11

EPA CompTox

10

EVMPD

10

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTIINFECTIVES FOR SYSTEMIC USE

2

GENITO URINARY SYSTEM AND SEX HORMONES

2

ALIMENTARY TRACT AND METABOLISM

1

DERMATOLOGICALS

1

MUSCULO-SKELETAL SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTIBACTERIALS FOR SYSTEMIC USE

1

ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS

1

ANTIFUNGALS FOR DERMATOLOGICAL USE

1

ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

1

ANTIMYCOTICS FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTIFUNGALS FOR TOPICAL USE

1

ANTIINFECTIVES

1

ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS

1

ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS

1

ANTIMYCOTICS FOR SYSTEMIC USE

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Antiinfectives

1

Antiinfectives and antiseptics for local oral treatment

1

Antiinflammatory preparations, non-steroids for topical use

1

Antiinflammatory products for vaginal administration

1

Imidazole and triazole derivatives

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Salts, Hydrates, Esters, etc.

8

Principal Form

4

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 12 results

First page disabled
Previous page disabled
1
Next page
Next page

CEFTRIAXONE

75J73V1629

Export Data
Search for Structure

Status:

US Approved Rx (2006)

First approved in 1984

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier family 22 member 8

Bacterial penicillin-binding protein

Solute carrier family 22 member 6

Solute carrier family 22 member 11

Conditions:

Acute bacterial otitis media

Lower respiratory tract infections

Urinary tract infections

Skin and skin structure infections

Pelvic inflammatory disease

Uncomplicated gonorrhea

Intra-abdominal infections

Bone and joint infections

Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life. Ceftriaxone is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Ceftriaxone has activity in the presence of some beta-lactamases, both ...

penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. It is approved for the treatment of lower respiratory tract infections, acute bacterial otitis media, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intraabdominal infection, meningitis, and surgical prophylaxis. Common adverse reactions include erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, pseudomembranous enterocolitis, hemolytic anemia, hypersensitivity reaction, kernicterus, renal failure, and lung injury. Vancomycin, amsacrine, aminoglycosides, and fluconazole are incompatible with Ceftriaxone in admixtures. Precipitation of Ceftriaxone-calcium can occur when Ceftriaxone for Injection is mixed with calcium-containing solutions in the same intravenous administration line.

NAPROXEN

57Y76R9ATQ

Export Data
Search for Structure

Status:

US Approved Rx (1993)

First approved in 1976

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Cyclooxygenase-1

Cyclooxygenase-2

Conditions:

Ankylosing spondylitis

Rheumatoid arthritis

Naproxen (naproxen sodium, NAPROSYN®) is a propionic acid derivative related to the arylacetic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). It is an anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and ...

its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout. The mechanism of action of the naproxen (naproxen sodium, NAPROSYN®), like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).

MICONAZOLE

7NNO0D7S5M

Export Data
Search for Structure

Status:

US Approved OTC

First approved in 1974

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Sphingosine-1-phosphate lyase 1

Cytochrome P450 51

Conditions:

Oropharyngeal candidiasis

Vulvovaginal candidiasis

Multiple sclerosis

Miconazole is a synthetic imidazole derivative, a topical antifungal agent for use in the local treatment of vaginal, and skin and nail infections due to yeasts and dermatophytes. It is particularly active against Candida spp., Trichophyton spp., Epi...

dermophyton spp., Microsporum spp. and Pityrosporon orbiculare (Malassezia furfur), but also possesses some activity against Gram-positive bacteria. It binds to the heme moiety of the fungal cytochrome P-450 dependent enzyme lanosterol 14-alpha-demethlyase. Inhibits 14-alpha-demethlyase, blocks formation of ergosterol and leads to the buildup of toxic methylated 14-a-sterols. Miconazole also affects the synthesis of triglycerides and fatty acids and inhibits oxidative and peroxidative enzymes, increasing the amount of active oxygen species within the cell.

MICONAZOLE, (R)-

C90U92KSVX

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ABSOLUTE)

CEFTRIAXONE, (E)-

8596N5F144

Export Data
Search for Structure

Status:

US Approved Rx (2006)

First approved in 1984

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier family 22 member 8

Bacterial penicillin-binding protein

Solute carrier family 22 member 6

Solute carrier family 22 member 11

Conditions:

Acute bacterial otitis media

Lower respiratory tract infections

Urinary tract infections

Skin and skin structure infections

Pelvic inflammatory disease

Uncomplicated gonorrhea

Intra-abdominal infections

Bone and joint infections

Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life. Ceftriaxone is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Ceftriaxone has activity in the presence of some beta-lactamases, both ...

penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. It is approved for the treatment of lower respiratory tract infections, acute bacterial otitis media, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intraabdominal infection, meningitis, and surgical prophylaxis. Common adverse reactions include erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, pseudomembranous enterocolitis, hemolytic anemia, hypersensitivity reaction, kernicterus, renal failure, and lung injury. Vancomycin, amsacrine, aminoglycosides, and fluconazole are incompatible with Ceftriaxone in admixtures. Precipitation of Ceftriaxone-calcium can occur when Ceftriaxone for Injection is mixed with calcium-containing solutions in the same intravenous administration line.

CEFTRIAXONE SODIUM ANHYDROUS

R598PB148Q

Export Data
Search for Structure

Status:

US Approved Rx (2006)

First approved in 1984

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier family 22 member 8

Bacterial penicillin-binding protein

Solute carrier family 22 member 6

Solute carrier family 22 member 11

Conditions:

Acute bacterial otitis media

Lower respiratory tract infections

Urinary tract infections

Skin and skin structure infections

Pelvic inflammatory disease

Uncomplicated gonorrhea

Intra-abdominal infections

Bone and joint infections

Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life. Ceftriaxone is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Ceftriaxone has activity in the presence of some beta-lactamases, both ...

penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. It is approved for the treatment of lower respiratory tract infections, acute bacterial otitis media, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intraabdominal infection, meningitis, and surgical prophylaxis. Common adverse reactions include erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, pseudomembranous enterocolitis, hemolytic anemia, hypersensitivity reaction, kernicterus, renal failure, and lung injury. Vancomycin, amsacrine, aminoglycosides, and fluconazole are incompatible with Ceftriaxone in admixtures. Precipitation of Ceftriaxone-calcium can occur when Ceftriaxone for Injection is mixed with calcium-containing solutions in the same intravenous administration line.

CEFTRIAXONE SODIUM

023Z5BR09K

Export Data
Search for Structure

Status:

US Approved Rx (2006)

First approved in 1984

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Solute carrier family 22 member 8

Bacterial penicillin-binding protein

Solute carrier family 22 member 6

Solute carrier family 22 member 11

Conditions:

Acute bacterial otitis media

Lower respiratory tract infections

Urinary tract infections

Skin and skin structure infections

Pelvic inflammatory disease

Uncomplicated gonorrhea

Intra-abdominal infections

Bone and joint infections

Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life. Ceftriaxone is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis. Ceftriaxone has activity in the presence of some beta-lactamases, both ...

penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. It is approved for the treatment of lower respiratory tract infections, acute bacterial otitis media, skin infections, urinary tract infections, pelvic inflammatory disease, bacterial septicemia, bone and joint infections, intraabdominal infection, meningitis, and surgical prophylaxis. Common adverse reactions include erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, pseudomembranous enterocolitis, hemolytic anemia, hypersensitivity reaction, kernicterus, renal failure, and lung injury. Vancomycin, amsacrine, aminoglycosides, and fluconazole are incompatible with Ceftriaxone in admixtures. Precipitation of Ceftriaxone-calcium can occur when Ceftriaxone for Injection is mixed with calcium-containing solutions in the same intravenous administration line.

NAPROXEN LYSINE

15X32OGO88

Export Data
Search for Structure

Status:

US Approved Rx (1993)

First approved in 1976

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Cyclooxygenase-1

Cyclooxygenase-2

Conditions:

Ankylosing spondylitis

Rheumatoid arthritis

Naproxen (naproxen sodium, NAPROSYN®) is a propionic acid derivative related to the arylacetic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). It is an anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and ...

its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout. The mechanism of action of the naproxen (naproxen sodium, NAPROSYN®), like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).

NAPROXEN AMINOBUTANOL

F5O9L39X2D

Export Data
Search for Structure

Status:

US Approved Rx (1993)

First approved in 1976

Class (Stereo):

CHEMICAL (RACEMIC)

Targets:

Cyclooxygenase-1

Cyclooxygenase-2

Conditions:

Ankylosing spondylitis

Rheumatoid arthritis

Naproxen (naproxen sodium, NAPROSYN®) is a propionic acid derivative related to the arylacetic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). It is an anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and ...

its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout. The mechanism of action of the naproxen (naproxen sodium, NAPROSYN®), like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).

NAPROXEN PIPERAZINE

R2A8B8HIPI

Export Data
Search for Structure

Status:

US Approved Rx (1993)

First approved in 1976

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Cyclooxygenase-1

Cyclooxygenase-2

Conditions:

Ankylosing spondylitis

Rheumatoid arthritis

Naproxen (naproxen sodium, NAPROSYN®) is a propionic acid derivative related to the arylacetic acid group of nonsteroidal anti-inflammatory drugs (NSAIDs). It is an anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and ...

its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout. The mechanism of action of the naproxen (naproxen sodium, NAPROSYN®), like that of other NSAIDs, is not completely understood but involves inhibition of cyclooxygenase (COX-1 and COX-2).

Showing 1 - 10 of 12 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1